Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.

Slides:

Advertisements

Similar presentations

A B Figure S1 pRS425pRS425-FCP1 Rpb3p ChIP efficiency (relative to wt promoter) C Ser2P / Rpb3p ChIP ratio (relative to wt promoter)

Advertisements

Supplemental Figure 1 A No. at risk T T T

Tfam 1  g empty vector 1  g Tfb2m 1  g Relative mRNA level * * p

Figure 1 HuR Tis11b HPRT VEGF Time (h) A 462 bp (VEGF 165 ) 332 bp (VEGF 121 ) 354 bp 111 bp 305 bp.

Lyn Tyrosine Kinase Regulates Androgen Receptor Expression and Activity in Castrate Resistant Prostate Cancer Anousheh Zardan, Ka Mun Nip, Daksh Thaper,

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Regulation of Cytochrome P450 2E1 Expression by Ethanol: Role of Oxidative Stress- mediated PKC/JNK/SP1 Pathway Mengyao Jin, Anusha Ande, Anil Kumar and.

 decimals/cc-7th-fracs-to-decimals/v/converting-fractions-to-decimals-example.

P2P6P10 Hcy Ctrl P2P6 P10 Ctrl Hcy Supplement Fig. I A B Suppl. Fig. I. Cell cycle and apoptotic effects of Hcy treated HUVECs senescence. Primary cultured.

B C Supplementary Figure 1 Control X0 Control X9  -HBx (mAb)  -HBx (rabbit serum) ABCEFD aa ABCEF X0 X9 (  D) A

1A IP/ Input Figure 1: E47 is present on tRNA genes 1B IgG TFIIB E47 Brf1 WB: Brf1 Input IP A) IP/Input enrichment of E47 at 6 active tRNA genes and one.

Supplemental Figure S1: Diagram to show previously reported interactions between EGFR and 23 other Egr1 target genes using Pathway Studio, Ariadne Inc.

Supplemental Table 1 Source and authentication of cell lines.

A B C D ** CpG-free Luc -7,200 -5,900 e2piNOS-luc -4,900 e1piNOS-luc

Figure 2. Effects of RUNX1 and PU. 1 siRNAs on CCR3 reporter activity

Progesterone receptor

HIF1 binds and stimulates the VEGFA promoter in normoxia.

Supplemental Figure S1 a b

A B Supplementary Figure 3

Volume 15, Issue 4, Pages (August 2004)

A B C Vinculin Vinculin HBP1 HBP1 p63 Loricrin Supplementary 2.

JQ1 directly represses the promoter activities of BRCA1 and RAD51

NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression

17β-estradiol, Progesterone, and Dihydrotestosterone Suppress the Growth of Human Melanoma by Inhibiting Interleukin-8 Production Naoko Kanda, Shinichi.

Volume 15, Issue 3, Pages (April 2016)

Volume 20, Issue 4, Pages (October 2011)

Volume 6, Issue 5, Pages (November 2004)

CHK1 downregulation upon ERG overexpression.

Volume 130, Issue 4, Pages (August 2007)

Volume 32, Issue 6, Pages e7 (December 2017)

Supplemental Figure 1A Pt Pt Pre-treatment

SUMO Promotes HDAC-Mediated Transcriptional Repression

Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing.

Volume 151, Issue 7, Pages (December 2012)

Volume 16, Issue 6, Pages (June 2015)

Volume 125, Issue 3, Pages (May 2006)

Xiaolong Wei, Hai Xu, Donald Kufe Cancer Cell

Supplementary Figure 1 IP: IgG HA 3HA-E2F1: cIAP1: wt K

Volume 138, Issue 2, Pages (July 2009)

Volume 31, Issue 4, Pages (August 2008)

Figure S4 control-siRNA Day 0 fes A-siRNA Day 3 fer 1-siRNA

Bo-Kuan Wu, Charles Brenner Cell Reports

Volume 27, Issue 3, Pages (August 2007)

Bernard et al, Supplementary Figure S1

Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate- Cancer-Associated Mutants Jian An, Chenji Wang, Yibin Deng, Long Yu,

Supplemental Figure 1 Patient 2.

Molecular Therapy Volume 20, (May 2012) DOI: /S (16)

Spatial and Temporal Recruitment of Androgen Receptor and Its Coactivators Involves Chromosomal Looping and Polymerase Tracking Qianben Wang, Jason S.

Nrf2 Promotes Keratinocyte Proliferation in Psoriasis through Up-Regulation of Keratin 6, Keratin 16, and Keratin 17 Luting Yang, Xueli Fan, Tingting.

Expression and Histone H4 Acetylation Levels of MAPK6 and WRKY53 in the HDT701 OX and RNAi Plants after M. oryzae Inoculation. Expression and Histone H4.

A B Supplementary Figure S1 PC3 cells Vehicle 3β-Adiol

Volume 9, Issue 5, Pages (December 2014)

Volume 36, Issue 3, Pages (November 2009)

Lhx2 binds to the promoter regions of the Sox9, Tcf4 and Lgr5 genes in keratinocytes. Lhx2 binds to the promoter regions of the Sox9, Tcf4 and Lgr5 genes.

CoCoA, a Nuclear Receptor Coactivator which Acts through an N-Terminal Activation Domain of p160 Coactivators Jeong Hoon Kim, Hongwei Li, Michael R Stallcup

Effect of M-cadherin RNAi on serum-starvation-induced apoptosis.

Class II HDACs are functionally redundant, but HDAC5 is the primary GLUT4 regulator in 3T3-L1 preadipocytes. Class II HDACs are functionally redundant,

Effect of M-cadherin RNAi and GSK-3β inhibition on myogenic differentiation of C2C12 myoblasts. Effect of M-cadherin RNAi and GSK-3β inhibition on myogenic.

Formation of the Androgen Receptor Transcription Complex

Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB

JAK inhibitors suppress IL-17–induced expression of IκB-ζ.

MTB1 Antagonizes MYC2 for DNA Binding.

PELP1 regulates the expression and activities of MMPs in ER-negative cells. PELP1 regulates the expression and activities of MMPs in ER-negative cells.

Overexpression of EP4 with cAMP-PKA signal activation promoted the castration-resistant progression of LNCaP cells through AR activation. Overexpression.

Pirh2 represses p73-dependent transactivation.

EGFR signaling regulates transcription of PDGFRβ gene.

scrambled si-CLOCK scrambled si-CLOCK scrambled si-CLOCK scrambled

MTB1 to MTB3 Are Direct Transcriptional Targets of MYC2.

A B C Name Sequence TIMP3 promoter

Presentation transcript:

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA as a percentage of input DNA after treatment with DHT for 0-2hrs (± doxycycline). IgG controls are given for comparison. B, ChIP analysis of AR and PHB binding to the KLK2 promoter in LNCaP/Luc/PHB-RNAi cells after treatment with DHT for 0-2hrs (± doxycycline). * = P<0.05 (t-test analysis).ß EnhancerNegativePromoterEnhancerNegativePromoterEnhancerNegativePromoter IgGARPHB No Dox No DHT No Dox DHT Dox No DHT Dox DHT

Supplemental Figure 2 a T No Dox +RNAi T Time after DHT treatment Enhancer Promoter No Dox +RNAi Taqman PCR IgG Control Figure 2 A, ChIP analysis of the PSA promoter and enhancer regions with a control rabbit IgG antibody, in LNCaP/Luc/PHB-siRNA cells treated with DHT over 0-2hours. B, ChIP analysis of AR and PHB binding (and IgG control) to the KLK2 promoter in the LNCaP/Luc/PHB- siRNA cells after treatment with DHT for 0-4hrs (± doxycycline). Enrichement due to IgG AR enrichment (fold increase) Enhancer Promoter

Supplemental Figure 3 a b * * * No dox+ RNAiNo dox+ RNAi KLK2TMPRSS2 Fold Increase in Expression Time after treatment (min) Figure 3 A. Taqman RT-PCR analysis of KLK2 and TMPRSS2 transcript levels collected at time intervals (0 – 8hr) from starved LNCaP/Luc/PHB-RNAi cells treated with 10nM DHT. ** = P<0.01, * = P<0.05 (t-test analysis). B, AR-mediated luciferase expression from LNCaP/Luc/PHB-siRNA cells treated with DHT or Androstenedione (0-10nM) for 24hrs (± doxycycline), transiently transfected with either empty pcDNA4 or pcDNA expressing PHB- cDNA coding region which is not targetted by PHB-RNAi pcDNA4-EmptypcDNA4-PHB wt No Dox PHB-RNAi pcDNA4-EmptypcDNA4-PHB wt No Dox PHB-RNAi Luciferase expression (foild increase) nM DHT nM ASD DHT Androstenedione

Supplemental Figure 4 PSA Fold Increase b DHT concentration (nM) Androstenedione concentration (nM) PSA Fold Increase No Dox Dox No Dox Dox LNCaP/pTER Scrambled Vector c PSA Fold Increase Figure 4. A, Taqman RT-PCR analysis of PSA transcript levels collected at time intervals (0-16hrs) from starved LNCaP/Luc/scrambled-siRNA cells treated with 10nM DHT or androstenedione. B, Taqman RT-PCR analysis of PSA transcripts from starved LNCaP/Luc/pcDNA4/TO- Empty cells treated with 0-100nM DHT or androstenedione. C, Taqman RT-PCR analysis of PSA transcripts from starved LNCaP/Luc/scrambled-siRNA cells treated with 0-100nM DHT or androstenedione.

Supplemental Figure 5 No Dox+ PHB-cDNA Bmax2669± ± Kd0.70 ± ± 0.08 No Dox + PHB-RNAi Bmax3034 ± ± Kd0.61 ± ±0.05 PHB-cDNA PHB-RNAi Figure 5. Scatchard analysis of [3H]-mibolerone binding to the AR in LNCaP/Luc/PHB-cDNA and RNAi cells. Binding maximum (Bmax) and dissociation constant (kd) are given for each cell line in the table.

Supplemental Figure actin TAP1Cyc DCaspase 7YY1TK1 No Dox PHB RNAi Gene expression (fold increase) TAP1 actin Cyc DPSA Eth DHT Gene expression (fold increase) a IFN+ IFN- IFN+ IFN No DoxPHB RNAi TAP1 expression (fold increase) c b Figure 6. A, Taqman RT-PCR analysis of TAP1, -actin, CyclinD and PSA transcripts from starved LNCaP cells treated with 10nM DHT or ethanol. B, Taqman RT-PCR analysis of b-actin, TAP1, Cyclin D, Caspase 7, YY1, TK transcript levels collected from LNCaP/Luc/PHB-RNAi cells (± doxycycline). C, Taqman RT-PCR analysis of TAP-1 transcripts from LNCaP/Luc/PHB-RNAi cells treated with 100U/ml g-IFN for 6hours.

Supplemental Figure 7 + Dox (PHB RNAi) No DNase DNA Marker + DNase Increased DNase sensitivity Figure 7. Ethidium bromide stained gel electrophoresis showing motility of DNA extracted from LNCaP/Luc/RNAi cells treated with increased amounts of doxycycline for 24hr and subjected to DNase digestion.

Supplemental Figure Scrambled PHB-siRNA PHB Scrambled PHB-siRNA PSA EthOH DHT Fold change b a LNCaPVCaPDu145C42C42b % expression of PHB (relative to LNCaP) Cell Line Figure 8. A, Taqman RT-PCR analysis of PHB transcript levels from LNCaP, VCaP, C42, C42b, Du145 and MCF-7 cells, normalized via absolute quantification against a standard curve generated using purified PHB RNA. B, Taqman RT-PCR analysis of PHB and PSA levels from starved VCaP cells treated with PHB-siRNA for 48hours and treated with DHT for 24hours, normalized to L19. In each case data represent mean of triplicate experiment and are representative of 2 or more independent experiments.

PCR primers for ChIP PSA Promoter Promoter (AREI)FOR5-TCTGCCTTTGTCCCCTAGAT-3 REV5-GCTAGCACTTGCTGTTCTGC-3 Promoter (AREII)FOR5-AGGGATCAGGGAGTCTCACA-3 REV5-GCTAGCACTTGCTGTTCTGC-3 Negative 1FOR5-CTGTGCTTGGAGTTTACCTGA-3 REV5-GCAGAGGTTGCAGTGAGCC-3 Negative 2FOR5-AGGGTATCACCAGCCCTTCT-3 REV5-GAGGATGTCGGCAGCTCTAC-3 Enhancer (AREIII)FOR5-ACAGACCTACTCTGGAGGAAC-3 REV5-AAGACAGCAACACCTTTTT-3 Upstream 1FOR5-TTTAGGGCTTCCCAAGATGA-3 REV5-TGTCACCGGGAAAAGAAAAC-3 Downstream FOR5-CTGTGAGTGCCCAACCCTAT-3 REV5-CTGGGGATGCTCATGTTTTTC-3 Taqman PCR primers for ChIP PSA Promoter PSA negative For5-TCCACTCCAGCTCTAAGATGGT-3 PSA negative Rev5-CAGGTAAACTCCAAGCACAGTGA-3 PSA negative probe 5-FAM-CAGAGGTGGATATAGATAATC-3 PSA promoter For5-GTGCATCCAGGGTGATCTAGTAATT-3 PSA promoter Rev5-CACACCCAGAGCTGTGGAA-3 PSA promoter probe 5-FAM-CTAGCACTTGCTGTTCTGC-3 PSA enhancer For5-TGACAGTAAACAAATCTGTTGTAAGAGACA-3 PSA enhancer Rev5-AGCAGGCATCCTTGCAAGAT-3 PSA enhancer probe 5-FAM-CCAGGCTTGCTTACTGTC-3 Primers for Other Gene Promoters (ChIP) KLK2 Enhancer For5-TTTATAATTGGGTTGAAAGCAGACCTA-3 Rev5-AGCAGATTTGTTTACTGTTCAGGACA-3 KLK2 NegativeFor5-TGGGTGATGTGGTTGGATTGG-3 Rev`5-CCCATGATAACCTCAACCAAAACCT-3 KLK2 PromoterFor5-GCCTCCAGACTGATCTAGTATGTGT-3 Rev5-CACACCCAGAGCTGTGGAA-3 actin promoter region 1For5-AAGGCAACTTTCGGAACGG-3 Rev5-TCCTCTTCCTCAATCTCGCTCTC-3 actin promoter region 2For5-GAGCTCTTGGAGGGCATGGA-3 Rev5-CTCTACCTCTCAAGCCCAGGT-3 TAP1 promoter (STAT binding region)For5-AACTGGTGCAAGTGGAAAGG-3 Rev5-GCCAGAAGCTCAGCCATTTA-3 Cyclin D Region AFor5-CTCCACCTCACCCCCTAAATC-3 Rev5-AGAGCCCAAAAGCCATCC-3 Cyclin D Region CFor5-CCGACTGGTCAAGGTAGGAAG-3 Rev5-ACAACCCCTGTGCAAGTTTC-3 Supplemental Table 1 Table 1: A list of the primer sets used for the ChIP analysis PCR for PSA, KLK2, ß- actin, TAP1 and CyclinD1 gene promoters.